Scribd
Upload
17 views4 pages

Population Health

Dr. Robert L. Quigley advocates for a value-based healthcare model focusing on performance, patient involvement, and prevention of cardiovascular disease (CVD), particularly among African Americans who face higher mortality rates. He proposes the use of LODOCO, a daily low dose anti-inflammatory medication, as a precision medicine tool to address health inequities and reduce CVD fatalities. The document emphasizes the importance of addressing social determinants of health and the potential barriers to implementing this approach in marginalized communities.

Uploaded by

tomatosakil
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
17 views4 pages

Population Health

Dr. Robert L. Quigley advocates for a value-based healthcare model focusing on performance, patient involvement, and prevention of cardiovascular disease (CVD), particularly among African Americans who face higher mortality rates. He proposes the use of LODOCO, a daily low dose anti-inflammatory medication, as a precision medicine tool to address health inequities and reduce CVD fatalities. The document emphasizes the importance of addressing social determinants of health and the potential barriers to implementing this approach in marginalized communities.

Uploaded by

tomatosakil
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd

1

Population Health

Student Name

Institutional Affiliation

Professor’s Name

Course Name

Date
2

Population Health

I selected Robert L. Quigley, MD, DPhil, International Healthcare Consultant.

Speaking on behalf of AGEPHA Pharma (LODOCO), Dr Quigley predicts a value-based

healthcare model based on provider performance, patient participation, and pathology

prevention. He highlights that African Americans are twice as likely to die of CVD as

they are exposed to biological determinants of health, including obesity and high blood

pressure. According to research by Hackler et al., biomarkers such as hs-CRP can be

used to explain the disparities in the occurrence of CVD among different races. Offering

the use of LODOCO, a daily low dose of anti-inflammatory medication, as a precision

medicine tool that can help bridge the gap of health inequities and reduce

cardiovascular-related fatalities.

In my opinion, Dr. Quigley's strategy is innovative and necessary. It is prevention-

based and equity-focused, transforming healthcare into a proactive approach to care.

CVD is a killer worldwide, and as inflammation has been identified as a key factor, anti-

inflammatory treatment will completely change the results. Racial differences in CVD

mortality are addressed through his call to involve African Americans, who are twice as

likely to succumb to CVD. This is necessary since healthcare should not just cure the

disease, but eliminate inequities brought about by the social determinants such as diet,

environment, and access. Precision medicine using LODOCO will be a viable and

realistic approach to health justice.

This approach relates to my personal life due to the history of hypertension and

obesity in my family, which predisposes us to cardiovascular disease. The idea of using

LODOCO as an early preventive measure leaves me with hope that individuals such as
3

my family could lower the risk of it before it turns out to be life-threatening. It also

encourages me as an individual to pay some attention to preventive health. However,

there are potential barriers, such as inaccessibility in low-income communities and

distrust of healthcare in marginalized groups. There is also the fear of the long-term

consequences of taking anti-inflammatories daily. Targeting systemic problems such

as poverty, education, and access to health services will help achieve this value-based

model.
4

Reference

Mullin, R. (2023, December 25). Population health, access, and equity in 2024. Health IT

Answers. [Link]

in-2024/

You might also like